Videos

Postictal Generalized EEG Suppression as a Biomarker for SUDEP: Nancy R. Foldvary-Schaefer, DO, FAAN

The professor of neurology at Boston University Chobanian & Avedisian School of Medicine talked about diagnostic tools and using memory aids for patients with cognitive impairment at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

Nancy R. Foldvary-Schaefer, DO, FAAN

Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhD

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic discussed how additional sensors in seizure monitoring for patients with epilepsy may help better manage the risk of SUDEP. [WATCH TIME: 3 minutes]

Lawrence Elmer, MD, PhD;Cheryl Fitzer-Attas, PhD

Understanding Reasons for Greater Disability, Loss of Deep Gray Matter in Latinx Patients With MS: Daniel Ontaneda, MD, PhD

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

Daniel Ontaneda, MD, PhD

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western University discussed a presentation at AAN 2023 characterizing the clinical and MRI features of Latinx with multiple sclerosis. [WATCH TIME: 4 minutes]

EDS Evaluation

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

Diagnosis of Narcolepsy

Personalized Care Plans for Patients With Parkinson Disease

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Stuart H. Isaacson, MD, FAAN

Collaborating With Primary Care Physicians for the Management of Patients With Myasthenia Gravis

Stuart H. Isaacson, MD, FAAN, offers insight into the importance of tailoring care to the individual when it comes to managing patients with Parkinson disease.

A. Gordon Smith, MD, FAAN

Investigational Agents for the Treatment of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, talks about the importance of collaboration and education amid advances in myasthenia gravis treatment, from new formulations and routes of administration to innovative targets.

A. Gordon Smith, MD, FAAN

Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

A. Gordon Smith, MD, FAAN, describes the landscape of investigational therapies for myasthenia gravis, including plasma cells, CAR-T, antigen-specific tolerance.

Peter J. Goadsby, MD, PhD, DSc

Effectiveness of Minimally Invasive Parafascicular Surgery in Intracerebral Hemorrhage: Andrew Russman, DO

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Andrew Russman, DO

Practice Pearls for Management of NMOSD

The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

The Unmet Needs in NMOSD

Approaches to NMOSD Treatment in Clinical Practice

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Unmet Needs in the RRMS Treatment Landscape

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Ahmed Zayed Obeidat, MD, PhD;Ravi Dukkipati, MD;Gabriel Pardo, MD, FAAN

Advances in the Management of Relapsing-Remitting Multiple Sclerosis (RRMS)

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.

Ahmed Zayed Obeidat, MD, PhD;Ravi Dukkipati, MD;Gabriel Pardo, MD, FAAN

Clinical Implications of Latest Therapeutic Data for Cognition in MS

Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.

Stephen Krieger, MD

Early Progress From the World Brain Study: Imad Najm, MD

Multiple sclerosis expert Stephen Krieger, MD, discusses what can be inferred from the latest data on disease-modifying therapies as it pertains to cognition, and the importance of assessing cognitive performance over time.

Imad Michel Najm, MD

Improving Diagnosis, Screening Patients More Efficiently in Alzheimer Disease: Katherine Turk, MD

The director of Cleveland Clinic’s Epilepsy Center provided an update on the World Brain Study, a large-scale, longitudinal study aimed to observe the early, underlying changes in neurological disorders. [WATCH TIME: 9 minutes]

Katherine Turk, MD

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

The behavioral neurologist at VA Boston Healthcare System talked about screening patients for mild cognitive impairment to improve diagnosis in Alzheimer disease at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

James Berry, MD, MPH

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

The Effects of Disease-Modifying Therapy on MS Cognitive Function

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Stephen Krieger, MD

Accuracy of DCTclock to Detect Cognitive Impairment: Ali Jannati, MD, PhD

Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.

Ali Jannati, MD, PhD

Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

Madhav R. Thambisetty, MD, PhD

April 24th 2023

Preserving Cognitive Status in Pediatric Multiple Sclerosis: Kimberly O’Neill, MD

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Kimberly O'Neill, MD

April 24th 2023